Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
Momo Dives Despite Price Target Hike; UBS Initiates Biotechs; Mercury Is A Buy. Instinet-Nomura hiked its price target on Momo (MOMO), UBS started Amgen (AMGN) and Gilead Sciences (GILD) at neutral while initiating Regeneron Pharmaceuticals (REGN) at buy, and JPMorgan started Mercury Systems (MRCY) at overweight. Momo Instinet-Nomura hiked its price target on China's social media firm to 39 from 34.